trending Market Intelligence /marketintelligence/en/news-insights/trending/kJoczyC3g0ocMrVTlmA7ew2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Zimmer Biomet adjusted Q4'16 profit surges

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Zimmer Biomet adjusted Q4'16 profit surges

Zimmer Biomet Holdings Inc. booked $434.1 million, or $2.14 per share, in fourth-quarter 2016 adjusted net income, as opposed to $428.3 million, or $2.09 per share, in the fourth quarter of 2015.

The S&P Capital IQ consensus normalized EPS estimate for the fourth quarter was $2.11.

The company's fourth-quarter 2016 sales surged 4.1% year over year to $2.01 billion while net sales for the full year lifted 28.1% to $7.68 billion when compared to 2015.

Zimmer Biomet saw its fourth-quarter 2016 GAAP income narrow 47.5% year over year to $66.6 million, or 33 cents per share, from $127 million, or 62 cents per share, in the corresponding quarter of 2015.

Full-year 2016 adjusted net earnings were up to $1.61 billion, or $7.96 per share, from $1.31 billion, or $6.90 per share, in 2015.

The S&P Capital IQ consensus normalized EPS estimate for the year was $7.95.

The company's full-year 2016 GAAP earnings increased to $302.9 million, or $1.50 per share, from $147 million, or 77 cents per share, in 2015.

Zimmer Biomet will target $8.50 to $8.68 in adjusted EPS and $4.37 to $4.67 in GAAP EPS during 2017.

The S&P Capital IQ consensus normalized EPS estimate for 2017 is $8.65.